Ocugen (NASDAQ:OCGN) Trading Down 7.2% – Here’s What Happened

Ocugen, Inc. (NASDAQ:OCGN) shares were down 7.2% during trading on Thursday . The company traded as low as $1.79 and last traded at $1.8180. Approximately 2,458,987 shares changed hands during trading, a decline of 57% from the average daily volume of 5,723,533 shares. The stock had previously closed at $1.96.

Key Stories Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target (implying large upside from current levels), which can attract speculative buying and institutional interest. Benzinga
• Positive Sentiment: Ocugen outlined plans for a 2026 BLA submission and expects three pivotal filings within three years, and said it is expanding leadership — a clear near- to mid-term regulatory pathway that could materially increase valuation on successful filings. Seeking Alpha
• Positive Sentiment: Enrollment for the OCU400 Phase 3 liMeliGhT trial (gene therapy for broad retinitis pigmentosa) is complete; topline Phase 3 data are expected in Q1 2027 — a major clinical milestone that could be value-driving if positive. GlobeNewswire
• Neutral Sentiment: Market commentary and press coverage highlighted stock movement after results (e.g., “Gains on Results”); this reflects short-term volatility as investors parse the mixed financials and development updates. BayStreet
• Neutral Sentiment: The full Q4 2025 earnings call transcript is available for investors to review management’s commentary and Q&A (useful for assessing cadence on spend, milestones, and timelines). Earnings Call Transcript
• Negative Sentiment: Q4 results: EPS loss of $0.06 (in line) but revenue came in negative/was substantially below expectations (reported -$0.19M vs. est. $0.86M), and the quarter showed a $17.7M loss with very negative margins and ROE — fundamentals that can pressure the stock until revenue/expense trends improve. Press Release

Wall Street Analyst Weigh In

OCGN has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Chardan Capital reissued a “buy” rating and set a $7.00 price objective on shares of Ocugen in a research note on Thursday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Ocugen presently has a consensus rating of “Hold” and an average target price of $7.00.

Ocugen Price Performance

The company’s 50-day moving average is $1.57 and its 200-day moving average is $1.42. The firm has a market capitalization of $537.22 million, a price-to-earnings ratio of -7.82 and a beta of 2.75. The company has a debt-to-equity ratio of 8.04, a current ratio of 1.85 and a quick ratio of 1.85.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 491.22%. The company had revenue of ($0.19) million for the quarter, compared to the consensus estimate of $0.86 million. On average, research analysts expect that Ocugen, Inc. will post -0.2 earnings per share for the current year.

Hedge Funds Weigh In On Ocugen

Large investors have recently modified their holdings of the company. Y Intercept Hong Kong Ltd purchased a new stake in shares of Ocugen during the 2nd quarter worth about $333,000. Creative Planning acquired a new position in Ocugen during the second quarter valued at approximately $57,000. Catalyst Funds Management Pty Ltd purchased a new stake in Ocugen during the second quarter worth approximately $130,000. XTX Topco Ltd acquired a new stake in shares of Ocugen in the second quarter worth $203,000. Finally, Rinkey Investments increased its position in shares of Ocugen by 1.2% in the second quarter. Rinkey Investments now owns 1,179,006 shares of the company’s stock worth $1,144,000 after acquiring an additional 14,500 shares in the last quarter. 10.27% of the stock is currently owned by hedge funds and other institutional investors.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.